The Definitive Peptide Research Reference Guide — Compound Review

Home Compounds BPC-157 TB-500 CJC-1295 Ipamorelin GLP-1 GHK-Cu Epithalon NAD+ Comparisons BPC-157 vs TB-500 Sermorelin vs Ipamorelin Semaglutide vs Tirzepatide Guides GHK-Cu Guide GHRH Analogues Ipamorelin Guide Peptide Reconstitution Guide Peptide Injection Sites Guide Peptide Storage Guide Semaglutide Dosage BPC-157 Dosage Research Guides Joint Pain Weight Loss Longevity Vendor Scoreboard All Vendor Comparisons Peptide Price Comparison Vendor Closures & Status How to Read a Peptide COA How to Vet a Peptide Vendor Why Purgo Labs Purgo Labs Review Purgo Labs Discount Code Where to Buy by Compound Legal Status Shop Purgo Labs

Tirzepatide vs Wegovy

Tirzepatide vs Wegovy (semaglutide 2.4 mg): the two most effective approved weight loss medications. SURMOUNT-1 vs STEP-1 data shows tirzepatide produces 6 percentage points more weight loss.

Clinical Trial Comparison

Wegovy (STEP-1): 14.9% weight loss at 68 weeks. Tirzepatide (SURMOUNT-1): 20.9% at 72 weeks. For a 250 lb subject: Wegovy ~37 lbs, tirzepatide ~52 lbs. SURPASS-CVOT direct comparison confirms tirzepatide superiority.

Mechanism Difference

Wegovy (semaglutide): GLP-1 receptor agonism only. Tirzepatide: dual GLP-1/GIP agonism. The GIP component enhances insulin sensitivity in adipose tissue and may reduce nausea — contributing to both greater efficacy and potentially better tolerability.

Cardiovascular Evidence

Semaglutide (SELECT trial): 20% reduction in major cardiovascular events. Tirzepatide: SURMOUNT-MMO cardiovascular outcomes trial ongoing. Semaglutide currently has stronger cardiovascular evidence.